Drug Trial Radar · NCT04480567
AAV Gene Therapy Study for Subjects with PKU
Last checked: Nov 19, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 24, 2020
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jul 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, dose escalation study to evaluate the safety, efficacy and tolerability of BMN 307 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of BMN 307 and will be followed for safety and efficacy.
Conditions
- Phenylketonuria (PKU)
Interventions
BMN 307Drug
AAV Gene Therapy Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in mean Plasma Phe levelsTime frame: baseline, week 12
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University of South Florida
Tampa, Florida
Morristown Medical Center
Morristown, New Jersey
University Hospital Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.